Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa
VH Tam, AN Schilling, G Vo, S Kabbara… - Antimicrobial agents …, 2005 - Am Soc Microbiol
Despite limited data, polymyxin B (PB) is increasingly used clinically as the last therapeutic
option for multidrug-resistant (MDR) gram-negative bacterial infections. We examined the in …
option for multidrug-resistant (MDR) gram-negative bacterial infections. We examined the in …
[PDF][PDF] Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa
VH Tam, AN Schilling, G Vo, S Kabbara… - ANTIMICROBIAL …, 2005 - academia.edu
Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa Page 1 ANTIMICROBIAL
AGENTS AND CHEMOTHERAPY, Sept. 2005, p. 3624–3630 Vol. 49, No. 9 …
AGENTS AND CHEMOTHERAPY, Sept. 2005, p. 3624–3630 Vol. 49, No. 9 …
[引用][C] Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa
VH TAM, AN SCHILLING, G VO… - Antimicrobial …, 2005 - pascal-francis.inist.fr
Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa CNRS Inist Pascal-Francis
CNRS Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …
CNRS Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …
Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.
VH Tam, AN Schilling, G Vo, S Kabbara… - Antimicrobial Agents …, 2005 - europepmc.org
Despite limited data, polymyxin B (PB) is increasingly used clinically as the last therapeutic
option for multidrug-resistant (MDR) gram-negative bacterial infections. We examined the in …
option for multidrug-resistant (MDR) gram-negative bacterial infections. We examined the in …
[HTML][HTML] Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa
VH Tam, AN Schilling, G Vo, S Kabbara… - Antimicrobial Agents …, 2005 - ncbi.nlm.nih.gov
Despite limited data, polymyxin B (PB) is increasingly used clinically as the last therapeutic
option for multidrug-resistant (MDR) gram-negative bacterial infections. We examined the in …
option for multidrug-resistant (MDR) gram-negative bacterial infections. We examined the in …
Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa
VH Tam, AN Schilling, G Vo, S Kabbara… - Antimicrobial Agents …, 2005 - hero.epa.gov
Despite limited data, polymyxin B (PB) is increasingly used clinically as the last therapeutic
option for multidrug-resistant (MDR) gram-negative bacterial infections. We examined the in …
option for multidrug-resistant (MDR) gram-negative bacterial infections. We examined the in …
Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa
VH Tam, AN Schilling, G Vo, S Kabbara… - Antimicrobial …, 2005 - scholars.uthscsa.edu
Despite limited data, polymyxin B (PB) is increasingly used clinically as the last therapeutic
option for multidrug-resistant (MDR) gram-negative bacterial infections. We examined the in …
option for multidrug-resistant (MDR) gram-negative bacterial infections. We examined the in …
Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa
VH Tam, AN Schilling, G Vo, S Kabbara… - Antimicrobial Agents …, 2005 - cir.nii.ac.jp
抄録< jats: title> ABSTRACT</jats: title>< jats: p> Despite limited data, polymyxin B (PB) is
increasingly used clinically as the last therapeutic option for multidrug-resistant (MDR) gram …
increasingly used clinically as the last therapeutic option for multidrug-resistant (MDR) gram …
[PDF][PDF] Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa
VH Tam, AN Schilling, G Vo, S Kabbara… - ANTIMICROBIAL …, 2005 - researchgate.net
Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa Page 1 ANTIMICROBIAL
AGENTS AND CHEMOTHERAPY, Sept. 2005, p. 3624–3630 Vol. 49, No. 9 …
AGENTS AND CHEMOTHERAPY, Sept. 2005, p. 3624–3630 Vol. 49, No. 9 …
Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa
VH Tam, AN Schilling, G Vo… - Antimicrobial …, 2005 - pubmed.ncbi.nlm.nih.gov
Despite limited data, polymyxin B (PB) is increasingly used clinically as the last therapeutic
option for multidrug-resistant (MDR) gram-negative bacterial infections. We examined the in …
option for multidrug-resistant (MDR) gram-negative bacterial infections. We examined the in …